Alkem Laboratories Limited (ALKEM) — Announcement

· NSE Neutral
📢 Key Event
Favorable tax appeal orders eliminate Rs. 660.77 crores in tax liability
🔄 What Changed
Removal of tax disallowances for AYs 2018-19 to 2022-23

Alkem Laboratories disclosed favorable tax appeal orders from the Commissioner of Income Tax (Appeals) for assessment years 2018-19 to 2022-23, deleting disallowances under Section 80-IE that had previously added Rs. 660.77 crores in tax liability. The orders, received on June 30, 2026, remove penalties related to deductions claimed for R&D expenditures. No material financial impact is expected, and the company confirmed the ruling aligns with prior tax positions. This resolves long-standing tax disputes and eliminates a potential cash outflow, improving earnings visibility and reducing uncertainty around past liabilities.

📄 View Original Announcement (PDF)

About Alkem Laboratories Limited (ALKEM)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹65,593.36 Cr P/E: 27.7 ROE: 19.8% ROCE: 22.1%

View full ALKEM stock details →

📡 Get AI alerts when ALKEM files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track ALKEM — Free

📊 More ALKEM filings

See all ALKEM filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

📡 Get AI alerts when ALKEM files new disclosures

Track ALKEM filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track ALKEM — Free

Free account · 2 AI queries/day